Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Pregnant Women Treated with Nirmatrelvir/Ritonavir (Paxlovid) Using Salivary Polymerase Chain Reaction: A Prospective Cohort Study.
Microorganisms
December 2024
Department of Obstetrics and Gynecology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, 138 Sheng-Li Road, Tainan 704, Taiwan.
Objectives: We aim to study the relative viral load using salivary polymerase chain reaction among pregnant women treated with Paxlovid.
Methods: Pregnant women with coronavirus disease 2019 were allocated to two groups: those receiving Paxlovid and those receiving no antiviral agents. We compared the nasopharyngeal and salivary relative viral loads and their changes in saliva specimens.
Evaluating Drug Interaction Risks: Nirmatrelvir & Ritonavir Combination (PAXLOVID) with Concomitant Medications in Real-World Clinical Settings.
Pathogens
November 2024
Department of Pharmacology, Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Prague, Czech Republic.
Background: This research article delves into the battle against the COVID-19 pandemic, focusing on the efficacy and, particularly, the safety of the combination of nirmatrelvir with ritonavir, which is found in the pharmaceutical product Paxlovid. This study aims to analyze the potential interactions of commonly prescribed medicinal products with Paxlovid, shedding light on its utilization in specific medical fields.
Methods: Prescription data from the Czech Republic's Institute of Health Information and Statistics (IHIS CR) was analyzed, covering 4 million COVID-19 patients and 87.
Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series.
Commun Med (Lond)
January 2025
Patient-Led Research Collaborative, Oakland, CA, USA.
Background: Prior case series suggest that a 5-day course of oral Paxlovid (nirmatrelvir/ritonavir) benefits some people with Long COVID, within and/or outside of the context of an acute reinfection. To the best of our knowledge, there have been no prior case series of people with Long COVID who have attempted longer courses of nirmatrelvir/ritonavir.
Methods: We documented a case series of 13 individuals with Long COVID who initiated extended courses (>5 days; range: 7.
COVID-19 residual symptoms and adverse drug reactions after oral antiviral therapy in the Singapore primary care setting.
Ann Acad Med Singap
December 2024
Clinical Research Unit, National Healthcare Group Polyclinics, Singapore.
Real-World Effectiveness of Bebtelovimab Versus Nirmatrelvir/Ritonavir in Outpatients with COVID-19.
Pulm Ther
December 2024
Eli Lilly and Company, Indianapolis, IN, USA.
Introduction: This real-world study assessed the effectiveness of bebtelovimab (BEB) versus nirmatrelvir/ritonavir (NR) among outpatients with COVID-19 during the Omicron variant era.
Methods: We conducted a cohort study evaluating patients treated with BEB or NR from February to August 2022 (study period). Follow-up began the day after treatment and continued for 30 days.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!